Evidence map›Paper›PMID 19685085›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2010

Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies.

Mariko Wada, Satoru Nagata, Masahiro Saito, Toshiaki Shimizu, Yuichiro Yamashiro, Takahiro Matsuki, Takashi Asahara, Koji Nomoto

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 70 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 11 pooled it
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 11 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Microbiome-gut-brain axis in cancer treatment-related psychoneurological toxicities and symptoms: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. The gut microbiome, symptoms, and targeted interventions in children with cancer: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Review
  17. FecalGastro hep advances · 2026
    Article
  18. Review
  19. Review
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mariko WadaDepartment of Laboratory for Probiotics Research, Juntendo University School of Medicine, Tokyo 113-8421, Japan. maro@juntendo.ac.jp
Satoru Nagata
Masahiro Saito
Toshiaki Shimizu
Yuichiro Yamashiro
Takahiro Matsuki
Takashi Asahara
Koji Nomoto
Juntendo University · JPYakult Central Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProbiotics are expected to be effective in prophylaxis of infection in cancer patient, since infections in neutropenics are mainly caused by endogenous flora through the intestinal mucosa. However, the experience with the use of probiotics in immunocompromised patients is limited, and precise fecal bacteria analysis has not been reported. The aim of the study was to evaluate the effects of the enteral administration of the probiotic, Bifidobacterium breve strain Yakult, on its ability to prevent infection, fecal micro flora, and intestinal environments in cancer patients on chemotherapy.

methodsA placebo-controlled trial was performed at Juntendo University Hospital. Patients with malignancies admitted for chemotherapy (n = 42) were randomized into two groups receiving probiotic or placebo. The effects on infectious complications, natural killer cells, fecal micro flora, fecal organic acid concentrations, and fecal pH were studied.

resultsThe frequency of fever and the use of intravenous antibiotics were lower in the probiotic group than the placebo group. The probiotic administration enhanced the habitation of anaerobes. Disruption of the intestinal microbiota after chemotherapy such as the increase in the population levels of Enterobacteriaceae was observed at more pronounced manner in the placebo group in comparison to the probiotic group. The concentrations of total organic acids were maintained most of the time at the normal level, which constantly maintained the pH below 7.0 only in the probiotic group.

conclusionThese data, although based on a limited number of patients and samples, suggest that administration of B. breve strain Yakult could be an effective approach for achieving clinical benefits in immunocompromised hosts by improving their intestinal environments.

Indexed as

BifidobacteriumAdolescentAntineoplastic AgentsBacterial InfectionsChildChild, PreschoolEnteral NutritionFecesHumansImmunocompromised HostInfantKiller Cells, NaturalLeukocyte CountNeoplasmsProbioticsAntineoplastic Agents

Identifiers

PMID19685085
OpenAlexW2014608392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.